Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CLXT · Entity 6658 | General Counsel, EVP-Corp Dev | July 20, 2017 | July 20, 2017 |
| LUMOS PHARMA, INC.(NLNK) · Entity 85102 | Director | May 12, 2017 | May 16, 2017 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | April 25, 2023 | May 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date July 20, 2017 · Filed July 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 98,000 |
Reported balance
Holding disclosure · report date 2017-07-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 98,000 F1: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on June 14, 2017 and vests 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.29 · Expires 2027-06-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-07-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The stock option to purchase shares of Calyxt, Inc. common stock was granted on June 14, 2017 and vests 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on June 14, 2017 and vests 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
F2: The stock option to purchase shares of Calyxt, Inc. common stock was granted on June 14, 2017 and vests 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
LUMOS PHARMA, INC.
Report date May 12, 2017 · Filed May 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.42 · Expires 2027-05-11 | Direct | 13,309 |
Reported balance
After 2017-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-12 · Grant · Acquired 13,309 · Balance 13,309 F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.
ZEVRA THERAPEUTICS, INC.
Report date April 25, 2023 · Filed May 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2033-04-24 | Direct | 39,200 |
Reported balance
After 2023-04-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-25 · Grant · Acquired 39,200 · Balance 39,200 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2023 Filed May 9, 2023 01:54 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001437749-23-013126 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2033-04-24 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:20 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001437749-22-016302 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-27 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 28, 2022. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-21-015182 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-16 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 17, 2021. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's sixth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 00:43 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001437749-20-013590 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the OTCQB Venture Market on the date of grant, June 19, 2020. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's fourth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013392 · rdgdoc.xml · nonDerivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,899 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 8,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009882 · rdgdoc.xml · nonDerivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,042 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008070 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001437749-18-010655 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-21 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 22, 2018. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 23, 2017 Filed May 24, 2017 21:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-17-010010 · rdgdoc.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-22 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 23, 2017. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:21 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,309 | $0.00 Strike: $17.42 | $0.00 |
DisclosureSEC source: 0001126234-17-000054 · wf-form4_149496966117610.xml · derivative · entry 1 Saluri Joseph · CIK 0001512131 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,309 Underlying: Common Stock · 13,309 shares Expires 2027-05-11 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.